ARTICLE | Clinical News
VT-1161: Additional Ph IIb REVIVE data
January 13, 2017 7:53 PM UTC
Additional data from the double-blind, U.S. Phase IIb REVIVE trial in 215 patients with recurrent vulvovaginal candidiasis showed that 150 and 300 mg doses of oral VT-1161 once daily for 7 days and th...
BCIQ Company Profiles
BCIQ Target Profiles